

Corporate Action Notice

February 9, 2017

Reverse Stock Split and Ratio Change

Soitec SA

DR CUSIP: 83409F109

DR ISIN: US83409F1093

DR Ticker Symbol: SLOIY

Ratio (DRs: Underlying Shares): 1:2

Please be advised that Soitec SA has announced a Share Consolidation of one (1) new share for every twenty (20) existing shares in the local market effective February 8, 2017.

As a result, BNY Mellon will effect a reverse stock split and a ratio change on the Soitec SA Depositary Receipt ("DR") program. Effective February 10, 2017, DR holders of Soitec SA are required on a mandatory basis to surrender their DR(s) for cancellation and exchange their "Old" DRs (CUSIP 83409F109) for "new" DRs (CUSIP 83409F208). DR holders will receive one (1) "New" Depositary Shares (DS) (CUSIP 83409F208) for every five (5) "Old" DSs (CUSIP 83409F109). Only whole DSs will be distributed.

Please note: A ratio change may impact the fees payable by DR investors.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

Effective Date: February 10, 2017

Exchange Rate: 1 "New" DS for 5 "Old" DSs

Old CUSIP: 83409F109

Old Ratio: 1 DS: 2 Ordinary shares

New CUSIP: 83409F208

New Ratio: 2 DSs: 1 Ordinary share

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

adrdesk@bnymellon.com

LONDON

Jacek Jankowski

Vice President

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON